Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial

Yan Gao, Xue-Ping Li, Xuan-Ye Zhang, Xiaoxiao Wang, Qichun Cai, Bing BAI, Li-Qin Ping, Ji-Chen Hong, Huiqiang Huang

Blood (2025) 146 (Supplement 1): 5517.

https://doi.org/10.1182/blood-2025-5517

Published: 2025

Journal Articles

Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): A single-arm, phase II trial

Qingqing Cai, Yi Xia, Qihua Zou, Jianbo Liu, Zijian Li, Shenrui Bai, Runhui Zheng, Shuling Zhang, Bing BAI, Xiaojie Fang, Xiaoxiao Wang, Man Nie, Hang Yang

Blood (2025) 146 (Supplement 1): 1906.

https://doi.org/10.1182/blood-2025-1906

Published: 2025

Journal Articles

Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study

Yuchen Zhang, Qingqing Cai, Yongping Song, Yexiong Li, Shunan Qi, Yi Xia, Shenrui Bai, Jun Cai, Bing BAI, Xiaojie Fang, Man Nie, Yi Cao

Blood (2025) 146 (Supplement 1): 3643.

https://doi.org/10.1182/blood-2025-3643

Published: 2025

Journal Articles

Preliminary result of first-line orelabrutinib plus R-CHOP in CD5-positive diffuse large B-cell lymphoma (Rocket trial): A single-arm, phase II trial

Qingqing Cai, Yi Xia, Shenrui Bai, Tao Zhan, Qinghua Lan, Jianbo Liu, Zi-Jian Li, Qingfang Zeng, Runhui Zheng, Shuling Zhang, Qihua Zou, Bing BAI, Xiaojie Fang, Xiaoxiao Wang, Man Nie, Hang Yang

Blood (2025) 146 (Supplement 1): 3690.

https://doi.org/10.1182/blood-2025-3690

Published: 2025

Journal Articles

Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial

Gao Yan, Xue-Ping Li, Xuan-Ye Zhang, Xiaoxiao Wang, Bing BAI, Li-Qin Ping, Qichun Cai, Jia-Ling Zhuang, Huiqiang Huang

Blood (2025) 146 (Supplement 1): 1965.

https://doi.org/10.1182/blood-2025-1965

Published: 2025

Journal Articles

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Gao Yan, Xue-Ping Li, Bing Bai, Xiaoxiao Wang, Xuanye Zhang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2024-205253

Published: 2024

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Blood (2024) 144 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2024-209224

Published: 2024

Journal Articles

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Gao Yan, Xue-Ping Li, Xiaoxiao Wang, Xiaoyu Hong, Bing Bai, Xuanye Zhang, Jialing Zhuang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2024-207630

Published: 2024

Journal Articles

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

Liqin Ping, Xiaoxiao Wang, Yan Gao, Bing Bai, He Huang, Linbo Cai, Hui Zhou, Changguo Shan, Zhiming Li, Mingyao Lai, Haixia He, Cheng Huang, Haoqing Chen, Ru Feng, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2023-185212

Published: 2023

Journal Articles

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fei Li, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yu-Hua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2023-186099

Published: 2023

Journal Articles

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

Yanxia He, Yan Gao, Xiaoxiao Wang, Bing Bai, Zhiming Li, Haixia He, Liqin Ping, Cheng Huang, Haoqing Chen, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6218.

https://doi.org/10.1182/blood-2023-186496

Published: 2023

Journal Articles

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Gao Yan, Liling Zhang, Wenyu Li, Xu Wei, Ru Feng, Xue-Ping Li, Yu Chen, Huijing Wu, Xiaoxiao Wang, Bing Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 1689.

https://doi.org/10.1182/blood-2023-186252

Published: 2023

Journal Articles

Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial

Gao Yan, Xiaoxiao Wang, Bing Bai, Xue-Ping Li, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 3737–3738.

https://doi.org/10.1182/blood-2022-166936

Published: 2022

Journal Articles

DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study

Gao Yan, Cheng Huang, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yanxia He, Liqin Ping, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 9393–9394.

https://doi.org/10.1182/blood-2022-165874

Published: 2022

Journal Articles

Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Xiaoxiao Wang, Yan Gao, Shanshan Yu, Bing Bai, Qiuxiang Ou, Liuqing Zhu, He Huang, Hui Zhou, Yang Shao, Linbo Cai, Hui-qiang Huang

Blood (2021) 138 (Supplement 1): 2481.

https://doi.org/10.1182/blood-2021-150658

Published: 2021

Journal Articles

Novel Induction Therapy for Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma (ENKTL) Treated By Anti-PD-1 Antibody Plus Histone Deacetylase Inhibitor Followed By P-GemOx Regimen

Gao Yan, Yujing Zhang, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2021) 138 (Supplement 1): 137.

https://doi.org/10.1182/blood-2021-147169

Published: 2021

Journal Articles

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Li Fei, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2021) 138 (Supplement 1): 1359.

https://doi.org/10.1182/blood-2021-152018

Published: 2021

Journal Articles

Association of Circulating Tumor DNA from the Cerebrospinal Fluid with High-Risk CNS Involvement in Patients with Diffuse Large B-Cell Lymphoma

Xiaoxiao Wang, Yan Gao, MD PhD, Changguo Shan, Mingyao Lai, Haixia He, Bing Bai, Li-qin Ping, Qixiang Rong, Ruyu Ai, Lei Wen, Zhaoming Zhou, Ruoying Yu, Qiuxiang Ou, Xue Wu, Xiaoxia Wang, Yang Shao, Linbo Cai, Hui-qiang Huang

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-134804

Published: 2020

Journal Articles

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-141752

Published: 2020

Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Yan Gao, MD PhD, Huiqiang Huang, MDPhD, Xiaoxiao Wang, Bing Bai, Liling Zhang, MD PhD, Yin Xiao, Xinxiu Liu, Wenyu Li, PhD, Wei Xu, MD PhD, Ru Feng, Yu Chen, Huijing Wu, Jibin Li, Xue Wu

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-134665

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial

Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): A single-arm, phase II trial

Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study

Preliminary result of first-line orelabrutinib plus R-CHOP in CD5-positive diffuse large B-cell lymphoma (Rocket trial): A single-arm, phase II trial

Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial

DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study

Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Novel Induction Therapy for Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma (ENKTL) Treated By Anti-PD-1 Antibody Plus Histone Deacetylase Inhibitor Followed By P-GemOx Regimen

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study

Association of Circulating Tumor DNA from the Cerebrospinal Fluid with High-Risk CNS Involvement in Patients with Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only